Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jun 25, 2020
Regeneron recognizes new combos to boost I-O drug Libtayo's cancer response PD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patients combat several types of tumors. However, many people either do not respond to these checkpoint inhibitors, or they eventually develop resistance...
Read More...
Oct 11, 2018
Streamlined solutions provided by Cognitive Clinical Trials (CCT) related to the treatment and prevention of Alzheimer’s disease Congnitive Clinical Trials (CCT) has introduced a new research model that prevail over the top obstacles being faced by the researchers related to the treatment and prevention of Alzheime...
Read More...
Mar 28, 2018
Novo Holdings optimistic about investments in life sciences Novo Holdings is planning to increase its investment in early & late stage biotechs. Its focus will be mainly in the U.S. and Europe. They are optimistic about the investment in life-science companies with their past experience. NMD gets USD 47 million...
Read More...
Jan 30, 2018
Spasticity is defined as a condition in which certain muscles are continuously contracted, resulting in stiffness or tightness of the muscles, which interferes with normal movement, speech and gait. It is also known as a motor disease which is characterized by a velocitydependent increase in tonic stretch reflexes w...
Read More...
Sep 19, 2017
Thrombolytic Sciences announced completion of Phase I TS01 trial A clinical stage vascular health and biotech company, Thrombolytic Science, LLC (TSI), announced the completion of its Phase I trial investigating TS01, which is a new-generation clot-dissolving therapy for the treatment of clot-induced diseases like i...
Read More...
Aug 26, 2016
The South San Francisco biotech startup, Denali Therapeutics, that had raised $217 million last year to fight Alzheimer’s, Parkinson’s and ALS, and an additional $130 million from investors in a private placement led by Baillie Gifford, a UK-based mutual fund, has finally spoken about its plans to use the fund. The...
Read More...
Dec 20, 2014
Gene Therapy: The “Hunt” for CNS disorders! Many companies have tried over the years to find a way to reverse the course of crippling central nervous system disorders like amyotrophic lateral sclerosis (a.k.a. Lou Gehrig’s disease) but have failed. Fortunately, Gene therapy has proven to be an answer to a wide ran...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper